What is the 13F Pro Quality Score for MRVI?

13F Pro ranks MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MRVI's current score at https://13fpro.ai/research/MRVI (free sign-up required for the full ranking).

Which hedge funds own the most MRVI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MRVI include GTCR, BRAIDWELL, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MRVI as soon as new 13F filings post.

Where does 13F Pro source MRVI data?

All MARAVAI LIFESCIENCES HOLDINGS, INC. fundamentals and ownership data come directly from SEC EDGAR. MARAVAI LIFESCIENCES HOLDINGS, INC. files with the SEC under CIK 1823239. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MRVI in?

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MRVI research updated on 13F Pro?

MRVI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MARAVAI LIFESCIENCES HOLDINGS, INC.(MRVI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1823239 MRVI stock profile & AI dashboard →

13F Pro Quality Score

14.5/100

Rank #2,758 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

8.6/100

Profitability

10.5/100

Balance Sheet

15.2/100

Earnings Quality

30.0/100

Free Cash Flow

13.9/100

Institutional Flow

11.6/100

Revenue Scale

24.6/100

Dilution Risk

11.6/100

MRVI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRVI at 14.5/100 on a 32-signal composite quality model, placing it at rank #2,758 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (8.6) and profitability (10.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MARAVAI LIFESCIENCES HOLDINGS, INC. reports quarterly revenue of $65.8M, net income of $-3.7M, free cash flow of $4.2M. Top institutional holders of MRVI by reported 13-F value include GTCR, BRAIDWELL, BlackRock,, based on the most recent SEC filings. MRVI trades on the Nasdaq exchange and files with the SEC under CIK 1823239. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MARAVAI LIFESCIENCES HOLDINGS, INC. directly from SEC EDGAR. MARAVAI LIFESCIENCES HOLDINGS, INC.'s 13F Pro composite quality score has ranged between 13 and 85 since 2022, currently 14.5 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about MARAVAI LIFESCIENCES HOLDINGS, INC.

Quirks, history, and lore behind MRVI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. life sciences company · small-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the range of roughly $200–300 million, having surged dramatically during the pandemic era before normalizing — a classic COVID tailwind story.
3
The History
Formed through the combination of several life-science tool businesses and taken public around 2020, right as its core products became suddenly very important to the world.
4
The Secret
Its bread and butter is making the biological raw materials — like nucleic acid production reagents — that other biotech and pharma companies need to build their own products.
5
The Lore
When mRNA vaccines became the world's most urgent manufacturing challenge, this company was already supplying key CleanCap capping technology used in their production.
6
The Giveaway
A life sciences holding company whose name blends the word for 'wonderful' in Spanish with a nod to biologics — ticker MRVI, the quiet enabler of the mRNA revolution.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$65.8M

Net Income

Q1 2026

$-3.7M

Free Cash Flow

Q1 2026

$4.2M

D/E Ratio

Q1 2026

1.16

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-28.3% YoY

$185.7MFY 2025

FY20 $284.1MFY23 $288.9MFY24 $259.2MFY25 $185.7M

Net Income

+9.7% YoY

$-130.8MFY 2025

FY20 $89.0MFY23 $-119.0MFY24 $-144.8MFY25 $-130.8M

Operating Income

+8.6% YoY

$-215.3MFY 2025

FY20 $119.9MFY23 $-31.6MFY24 $-235.6MFY25 $-215.3M

EPS (Diluted)

+14.3% YoY

$-0.90FY 2025

FY20 $2.36FY23 $-0.90FY24 $-1.05FY25 $-0.90

Total Assets

-23.6% YoY

$770.6MFY 2025

FY20 $1.27BFY23 $1.49BFY24 $1.01BFY25 $770.6M

Total Debt

-1.4% YoY

$297.2MFY 2025

FY20 $540.6MFY23 $529.6MFY24 $301.4MFY25 $297.2M

Op. Cash Flow

-871.2% YoY

$-57.6MFY 2025

FY20 $152.2MFY23 $126.2MFY24 $7.5MFY25 $-57.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019
Revenue	$185.7M -28.3%	$259.2M -10.3%	$288.9M +1.7%	$284.1M +98.5%	$143.1M
Net Income	$-130.8M +9.7%	$-144.8M -21.7%	$-119.0M -233.8%	$89.0M +2090.4%	$-4.5M
Operating Income	$-215.3M +8.6%	$-235.6M -644.5%	$-31.6M -126.4%	$119.9M +399.8%	$24.0M
EPS (Diluted)	$-0.90 +14.3%	$-1.05 -16.7%	$-0.90 -138.1%	$2.36 +7966.7%	$-0.03
Total Assets	$770.6M -23.6%	$1.01B -32.2%	$1.49B +17.1%	$1.27B	—
Total Debt	$297.2M -1.4%	$301.4M -43.1%	$529.6M -2.0%	$540.6M	—
Operating Cash Flow	$-57.6M -871.2%	$7.5M -94.1%	$126.2M -17.1%	$152.2M +531.1%	$24.1M

AI Insight: MRVI Financial Trends

Q1 2026 revenue rebounded to $66M with operating loss nearly eliminated at -$2M, but equity has eroded 51% from Q2 2024 levels.

• Revenue fell from $73M in Q2 2024 to a trough of $42M in Q3 2025, then recovered to $66M in Q1 2026.

• Operating loss narrowed sharply to -$2M in Q1 2026 from -$66M in Q2 2025 and -$59M in Q4 2025.

• Operating cash flow turned positive at $9M in Q1 2026 after five consecutive quarters of negative or near-zero OCF.

• Total debt declined from $528M in Q2 2024 to $246M in Q1 2026, reducing leverage materially.

⚠ Equity has collapsed from $437M in Q2 2024 to $212M in Q1 2026, reflecting cumulative net losses eroding book value.

⚠ Revenue recovery to $66M in Q1 2026 must sustain — prior rebounds stalled, with revenue sliding to new lows.

⚠ Net losses persist in every quarter; Q1 2026's -$4M loss is the smallest, but profitability remains unachieved.

AI Insight: MRVI Ratio Trends

Q1 2026 shows dramatic margin recovery to -3.3% operating and -5.7% net, but TTM figures reveal persistently deep losses masking the true trend.

• Operating margin improved sharply from -117.9% in Q4 2025 to -3.3% in Q1 2026, the least negative reading in the entire dataset.

• ROIC recovered to -1.9% in Q1 2026 from a trough of -75.9% in Q3 2024, though it remains negative throughout all periods.

• TTM operating margin stands at -82.2% and TTM NPM at -51.1%, reflecting sustained deep losses over the trailing twelve months.

• D/E ratio rose from 0.93 in Q4 2024 to 1.40 in Q4 2025 before easing to 1.16 in Q1 2026, signaling lingering leverage pressure.

⚠ Q1 2026 margin improvement may be seasonal or one-off; TTM metrics at -82.2% op margin warn against extrapolating a single quarter's result.

⚠ D/E at 1.16 with all return metrics still negative raises refinancing risk if losses persist into Q2 2026.

⚠ Whether Q1 2026's near-breakeven operating margin (-3.3%) marks a genuine inflection or a transient improvement is the key watch point.

Get alerted when MRVI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MARAVAI LIFESCIENCES HOLDINGS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MRVI

GTCR LLC
$57.0M20,150,005 sh
BRAIDWELL LP
$29.0M10,240,164 sh
BlackRock, Inc.
$26.4M9,345,268 sh
12 West Capital Management LP
$20.5M7,260,195 sh
MACKENZIE FINANCIAL CORP
$17.8M6,306,425 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.4M5,449,702 sh
RENAISSANCE TECHNOLOGIES LLC
$12.1M4,264,689 sh
Tejara Capital Ltd
$9.9M3,495,187 sh
Monaco Asset Management SAM
$9.7M3,421,020 sh
MORGAN STANLEY
$9.4M3,319,325 sh

Fund	Value	Shares
GTCR LLC	$57.0M	20,150,005
BRAIDWELL LP	$29.0M	10,240,164
BlackRock, Inc.	$26.4M	9,345,268
12 West Capital Management LP	$20.5M	7,260,195
MACKENZIE FINANCIAL CORP	$17.8M	6,306,425
VANGUARD CAPITAL MANAGEMENT LLC	$15.4M	5,449,702
RENAISSANCE TECHNOLOGIES LLC	$12.1M	4,264,689
Tejara Capital Ltd	$9.9M	3,495,187
Monaco Asset Management SAM	$9.7M	3,421,020
MORGAN STANLEY	$9.4M	3,319,325

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MRVI on your watchlist

Track score changes the day MARAVAI LIFESCIENCES HOLDINGS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MRVI a good stock to buy?

13F Pro's AI-powered analysis of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRVI are available on the MRVI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MRVI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRVI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MARAVAI LIFESCIENCES HOLDINGS, INC.'s investment landscape.